Scientific Perspectives Logo

SCIENTIFIC PERSPECTIVES™

Test your knowledge of the assessment and management of IgA Nephropathy (IgAN)

Take a quiz on IgAN

Header Boxes

QUESTION 1 of 3:

IgAN, also known as Berger’s disease, is a leading cause of chronic kidney disease.1,2 Which of the following is/are true regarding factors associated with IgAN?1-6

YOUR ANSWER:

A.
Most patients with IgAN will develop ESKD within their lifetime
B.
Proteinuria and hematuria are common presentations of IgAN
C.
IgAN mostly affects older patients
D.
A and B only
E.
All of the above

CORRECT ANSWER IS:

D. A and B only

Adult Icon

IgAN is frequently diagnosed in adults aged 20-40 years, often incidentally3-5

Proteinuria and Hematuria medicine bottle icons

Patients may be asymptomatic in the early stages of the disease, but as IgAN progresses, hematuria and proteinuria are the most commonly presenting symptoms6

Proteinuria is present in approximately 75% of patients with IgAN and is a well-known, early, and sensitive indicator of progressive disease2,6a

Worsening kidney function arrow icon

Worsening kidney function may lead to CKD and ultimately ESKD requiring dialysis and/or kidney transplantation1,3,4,7,8

ESKD icon

Most patients with IgAN develop ESKD within their lifetime4,9

aRetrospective analysis using data from the Adelphi IgAN Disease Specific Programme. Average percentage of participants with proteinuria at the time of diagnosis in the US, EU (France, Germany, Italy, and Spain), and Asia (China and Japan) was 69%, 72%, and 78%, respectively.6

ESKD=end-stage kidney disease; IgA=immunoglobulin A.

References:

  1. Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176-194.
  2. Cattran DC, Floege J, Coppo R. Evaluating progression risk in patients with immunoglobulin A nephropathy. Kidney Int Rep. 2023;8(12):2515-2528.
  3. Lai KN, Tang SCW, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.
  4. Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738.
  5. Cheung CK, Boyd JKF, Feehally J. Evaluation and management of IgA nephropathy. Clin Med. 2012;12(6 Suppl):s27-s30.
  6. Roccatello D, Kattlun J, Przybysz R, et al. Real-world signs and symptoms at diagnosis in patients with IgA nephropathy. Nephrol Dial Transplant. 2022;37(suppl 3):i159.